Any new company wanting to make waves in applying artificial intelligence to drug discovery will need deep pockets and a top-tier science and management team – and startup
BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third
Back in the picturesque West End of London, even a sudden, torrential downpour could not dampen the spirits on 12th March as speakers and attendees returned once more to the Hilton Hotel in
Germany’s Merck KGaA has partnered with techbio company Caris Discovery in a $1.4 billion alliance that will apply artificial intelligence to the design of antibody-drug c
The pace of change in drug discovery and clinical development has been unmatched in recent years, with technologies such as AI accelerating these processes.
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.